4BIO Capital
Therese Liechtenstein is an experienced investment professional currently serving as an Investment Director at 4BIO Capital since November 2024. Previously, Therese held multiple roles at M Ventures, including Senior Investment Director and Investment Director in the Biotech sector, from July 2018 to September 2024. Therese has also served on the boards of several biotech companies, including ReproNovo, DISCO Pharmaceuticals GmbH, Future Fertility, Altoida, Inc., Theolytics, Anavo Therapeutics BV, and FoRx Therapeutics, demonstrating a strong commitment to advancing innovation in this field. Educational qualifications include a Doctor of Philosophy (PhD) in Cancer Immunology and Immunotherapy from UCL, a Master of Science (MSc) in Medical Biology from the University of Amsterdam, and a Bachelor of Arts (BA) in Biology and Business Studies from New York University.
This person is not in any teams
This person is not in any offices
4BIO Capital
4BIO Capital is an international venture capital firm focused solely on the advanced therapies sector. 4BIO’s objective is to invest in, support, and grow early stage companies developing treatments in areas of high unmet medical need, with the ultimate goal of ensuring access to these potentially curative therapies for all patients. Specifically, it looks for viable, high-quality opportunities in cell and gene therapy, RNA-based therapy, targeted therapies, and the microbiome. The 4BIO team comprises leading advanced therapy scientists and experienced life science investors who have collectively published over 250 scientific articles in prestigious academic journals including Nature, The Lancet, Cell, and the New England Journal of Medicine. 4BIO has both an unrivalled network within the advanced therapy sector and a unique understanding of the criteria that define a successful investment opportunity in this space. For more information, please visit www.4biocapital.com